Trials / Unknown
UnknownNCT02752516
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics
Phase I Additional Study of Tolerance and Pharmacokinetics of Anlotinib in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics.To further study the pharmacokinetic characteristics of Anlotinib in the human body, recommend a reasonable regimen for subsequent research.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent |
Timeline
- Start date
- 2016-04-27
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2016-04-27
- Last updated
- 2017-09-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02752516. Inclusion in this directory is not an endorsement.